Analyst: Zegalogue launch should be "plug and play" for Novo Nordisk
Novo Nordisk’s well-oiled machine has good synergies with Zealand Pharma’s rescue pen, Zegalogue, says a Sydbank analyst, predicting that the product’s year-end revenues will grow due to the deal.
by mikkel holmgaard winding, translated by daniel pedersen
The sales and marketing muscles behind rescue pen Zegalogue (dasiclugon) will be beefed up by Novo Nordisk taking over the global marketing rights from Zealand Pharma, assesses Sydbank analyst Søren Løntoft Hansen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk licenses hypoglycemia drug from Zealand Pharma
For subscribers
